✦ LIBER ✦

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

✍ Scribed by Janne, P. A.; Wang, X.; Socinski, M. A.; Crawford, J.; Stinchcombe, T. E.; Gu, L.; Capelletti, M.; Edelman, M. J.; Villalona-Calero, M. A.; Kratzke, R.; Vokes, E. E.; Miller, V. A.

Book ID: 111677579
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 170 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.40.1315

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Study of Pulse Erlot

Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non-Small-Cell Lung Cancer

✍ Riely, G. J.; Rizvi, N. A.; Kris, M. G.; Milton, D. T.; Solit, D. B.; Rosen, N.; 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 140 KB

Randomized Phase II Trial of Erlotinib o

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2

✍ Lilenbaum, R.; Axelrod, R.; Thomas, S.; Dowlati, A.; Seigel, L.; Albert, D.; Wit 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

Randomized phase II trial of first-line

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer

✍ Ahn, Myung-Ju; Yang, James Chih-Hsin; Liang, Jun; Kang, Jin-Hyoung; Xiu, Qingyu; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 550 KB

6508 ORAL CP-751, 871, an anti-IGF-IR an

6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

✍ Paz-Ares, L.; Pollak, M.N.; Eisenberg, P.D.; Blakely, L.J.; Haluska, P.; Cohen, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

O-086a Randomized phase II/III trial of

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

✍ Sandler, A.B.; Gray, R.; Brahmer, J.; Dowlati, A.; Schiller, J.H.; Perry, M.C.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 151 KB